FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897516580> ?p ?o ?g. }

• W2897516580 abstract "Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition of TNF-α inhibitors such as infliximab (IFX) may expedite symptom resolution and shorten CS duration. Thus, we conducted the first retrospective study, to our knowledge, evaluating symptom resolution in patients with irEC treated with and without IFX.Data were collected from the medical records of patients diagnosed with irEC. The primary endpoint was time to symptom resolution for irEC for cases managed with IFX plus CS (IFX group) versus CS alone (CS group). Duration of CS, overall survival (OS), and time to treatment failure (TTF) were secondary endpoints.Among 75 patients with irEC, 52% received CS alone, and 48% received IFX. Despite higher grade colitis in the IFX group (grade 3/4: 86% vs. 34%; p < 0.001), median times to diarrhea resolution (3 vs. 9 days; p < 0.001) and to steroid titration (4 vs. 13 days; p < 0.001) were shorter in the IFX group than in the CS group without a negative impact on TTF or OS. Total steroid duration (median 35 vs. 51 days; p = 0.150) was numerically lower in the IFX group.Despite higher incidence of grade 3/4 colitis, IFX added to CS for the treatment of patients with irEC was associated with a significantly shorter time to symptom resolution. The data suggest that early introduction of IFX should be considered for patients with irEC until definitive prospective clinical trials are conducted." @default.
• W2897516580 created "2018-10-26" @default.
• W2897516580 creator A5000768609 @default.
• W2897516580 creator A5000817838 @default.
• W2897516580 creator A5004685117 @default.
• W2897516580 creator A5006246174 @default.
• W2897516580 creator A5011016537 @default.
• W2897516580 creator A5018587731 @default.
• W2897516580 creator A5018938811 @default.
• W2897516580 creator A5019203117 @default.
• W2897516580 creator A5027845051 @default.
• W2897516580 creator A5028161783 @default.
• W2897516580 creator A5029017725 @default.
• W2897516580 creator A5029086097 @default.
• W2897516580 creator A5030834372 @default.
• W2897516580 creator A5033798832 @default.
• W2897516580 creator A5034338936 @default.
• W2897516580 creator A5035218748 @default.
• W2897516580 creator A5035468368 @default.
• W2897516580 creator A5035661806 @default.
• W2897516580 creator A5048082120 @default.
• W2897516580 creator A5048327749 @default.
• W2897516580 creator A5058653922 @default.
• W2897516580 creator A5062227471 @default.
• W2897516580 creator A5073007668 @default.
• W2897516580 creator A5080216618 @default.
• W2897516580 date "2018-10-11" @default.
• W2897516580 modified "2023-10-13" @default.
• W2897516580 title "Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis" @default.
• W2897516580 cites W1600348345 @default.
• W2897516580 cites W1845726423 @default.
• W2897516580 cites W1901931884 @default.
• W2897516580 cites W2006091295 @default.
• W2897516580 cites W2013136814 @default.
• W2897516580 cites W2028547258 @default.
• W2897516580 cites W2095799455 @default.
• W2897516580 cites W2105057287 @default.
• W2897516580 cites W2109653150 @default.
• W2897516580 cites W2118443170 @default.
• W2897516580 cites W2128758225 @default.
• W2897516580 cites W2168200807 @default.
• W2897516580 cites W2222086386 @default.
• W2897516580 cites W2265285917 @default.
• W2897516580 cites W2341285800 @default.
• W2897516580 cites W2527905628 @default.
• W2897516580 cites W2529373149 @default.
• W2897516580 cites W2529484692 @default.
• W2897516580 cites W2549481046 @default.
• W2897516580 cites W2572174216 @default.
• W2897516580 cites W2588916311 @default.
• W2897516580 cites W2736166064 @default.
• W2897516580 cites W2747028021 @default.
• W2897516580 cites W2753432434 @default.
• W2897516580 cites W2754843476 @default.
• W2897516580 cites W2768429453 @default.
• W2897516580 cites W2779658193 @default.
• W2897516580 cites W2792937256 @default.
• W2897516580 cites W2797675588 @default.
• W2897516580 doi "https://doi.org/10.1186/s40425-018-0412-0" @default.
• W2897516580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6469141" @default.
• W2897516580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30995944" @default.
• W2897516580 hasPublicationYear "2018" @default.
• W2897516580 type Work @default.
• W2897516580 sameAs 2897516580 @default.
• W2897516580 citedByCount "118" @default.
• W2897516580 countsByYear W28975165802018 @default.
• W2897516580 countsByYear W28975165802019 @default.
• W2897516580 countsByYear W28975165802020 @default.
• W2897516580 countsByYear W28975165802021 @default.
• W2897516580 countsByYear W28975165802022 @default.
• W2897516580 countsByYear W28975165802023 @default.
• W2897516580 crossrefType "journal-article" @default.
• W2897516580 hasAuthorship W2897516580A5000768609 @default.
• W2897516580 hasAuthorship W2897516580A5000817838 @default.
• W2897516580 hasAuthorship W2897516580A5004685117 @default.
• W2897516580 hasAuthorship W2897516580A5006246174 @default.
• W2897516580 hasAuthorship W2897516580A5011016537 @default.
• W2897516580 hasAuthorship W2897516580A5018587731 @default.
• W2897516580 hasAuthorship W2897516580A5018938811 @default.
• W2897516580 hasAuthorship W2897516580A5019203117 @default.
• W2897516580 hasAuthorship W2897516580A5027845051 @default.
• W2897516580 hasAuthorship W2897516580A5028161783 @default.
• W2897516580 hasAuthorship W2897516580A5029017725 @default.
• W2897516580 hasAuthorship W2897516580A5029086097 @default.
• W2897516580 hasAuthorship W2897516580A5030834372 @default.
• W2897516580 hasAuthorship W2897516580A5033798832 @default.
• W2897516580 hasAuthorship W2897516580A5034338936 @default.
• W2897516580 hasAuthorship W2897516580A5035218748 @default.
• W2897516580 hasAuthorship W2897516580A5035468368 @default.
• W2897516580 hasAuthorship W2897516580A5035661806 @default.
• W2897516580 hasAuthorship W2897516580A5048082120 @default.
• W2897516580 hasAuthorship W2897516580A5048327749 @default.
• W2897516580 hasAuthorship W2897516580A5058653922 @default.
• W2897516580 hasAuthorship W2897516580A5062227471 @default.
• W2897516580 hasAuthorship W2897516580A5073007668 @default.
• W2897516580 hasAuthorship W2897516580A5080216618 @default.
• W2897516580 hasBestOaLocation W28975165801 @default.
• W2897516580 hasConcept C120665830 @default.
• W2897516580 hasConcept C121332964 @default.
• W2897516580 hasConcept C126322002 @default.

• next